It would be worthwhile to understand whether cell-specific differences exist in the crosstalk between SG formation and NLRP3 inflammasome activation for future clinical trials and to develop targeted DDX3X drugs for the treatment of NASH. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.